Chen A R
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-5001, USA.
Pediatr Transplant. 1999;3 Suppl 1:78-86. doi: 10.1034/j.1399-3046.1999.00053.x.
Metastatic and recurrent pediatric solid tumors usually respond to chemotherapy but are likely to recur. Because of steep dose-response relationships, HDT requiring hematopoietic rescue may improve outcome. This strategy has recently been shown to be effective for metastatic neuroblastoma. Metastatic Ewing's sarcoma appears to be a closely analogous situation, and promising phase II studies suggest that a definitive trial of efficacy would be appropriate. Phase I or II trials remain appropriate and are needed to define further the efficacy of HDT for most other poor prognosis pediatric solid tumors.
转移性和复发性小儿实体瘤通常对化疗有反应，但很可能复发。由于剂量反应关系陡峭，需要造血救援的大剂量化疗（HDT）可能会改善治疗结果。最近已证明该策略对转移性神经母细胞瘤有效。转移性尤因肉瘤似乎是一种非常类似的情况，有前景的II期研究表明进行疗效的确定性试验是合适的。I期或II期试验仍然合适，并且需要进一步确定HDT对大多数其他预后不良的小儿实体瘤的疗效。
